MDMA in therapy: differences between trip therapy and PAP

The terms “trip therapy” and “psychedelic-assisted psychotherapy” (PAP) are often used interchangeably, while in practice they can mean something different. Especially when it comes to mdma As is done, it is important to remain careful: not only regarding language, but also regarding expectations, safety, and context. In this article, we explain the differences, what you can and cannot expect, and why harm reduction currently plays a central role in practice.

What do we mean by PAP (psychedelic-assisted psychotherapy)?

In psychedelic-assisted psychotherapy, psychotherapy is central. In this approach, the substance, such as MDMA or psilocybin, is viewed as a tool that can support the therapeutic process. In research, this is usually elaborated into a clear protocol involving preparation, a session (day), and integration. There is also typically a careful selection process, and work involves measurement points and reporting.

It is important to state soberly: PAP with MDMA is currently not “freely available” in the Netherlands as a standard treatment. MDMA sessions can currently only take place within scientific research take place, or be discussed in practice in a harm-reduction context. This means that the way in which people talk about and work with it depends heavily on the framework, the goals, and the responsibilities of those involved.

What is often meant by trip therapy?

“Trip therapy” is not a strictly defined medical term. In everyday use, it usually refers to a guided psychedelic experience in which the emphasis is on the experience itself, often with attention to preparation and integration. In the Netherlands, in practice, this frequently involves legal substances such as psilocybin truffles, because they occupy a different legal position than, for example, MDMA.

Trip therapy can range from well-structured guidance with clear agreements to more informal forms. Therefore, it is especially important to ask follow-up questions: who is providing the guidance, what training and experience is available, what does the safety plan look like, and how are aftercare and integration handled?

The most important difference: framework, claims and responsibility

The biggest difference between PAP and trip therapy often lies not in the intention (personal growth or symptom reduction), but in the frame:

At PAP There is typically a clinical or research protocol with defined roles (therapist, research team), inclusion and exclusion criteria, and a fixed methodology. The language is usually medical and scientific, with an emphasis on outcomes, measurability, and safety within a protocol.

In trip therapy The setting is usually less clinical, and the support can vary. Sometimes there is indeed a strong therapeutic component (such as extensive intake, preparation, and integration), but the term itself does not guarantee this. Therefore, it is wise to look at concrete elements: screening, set and setting, crisis plan, and how someone copes with difficult experiences.

A second difference is the way of communicating. PAP will generally formulate more cautiously, referring to research and limitations. In the broader market surrounding trip therapy, you may sometimes encounter more assertive language. For the reader, it is helpful to translate claims into questions: “What is this based on?”, “For whom does this apply and for whom does it not?” and “What uncertainties are there?”

Where does MDMA fit into this story?

MDMA is being investigated in international studies in relation to psychotherapy, including for trauma-related complaints. Researchers often focus on the combination of the substance with a carefully constructed therapeutic context, including preparation and integration. At the same time, it is crucial to emphasize that research results do not automatically mean that it is safe or appropriate for everyone, or that the same results can be expected outside of research.

In practice in the Netherlands, the following also applies: MDMA sessions can currently only be discussed and approached within scientific research or via harm reduction.. In this context, harm reduction means limiting risks as much as possible through good information, screening where possible, attention to set and setting, and clear agreements regarding boundaries, aftercare, and referral when necessary. It is not a guarantee of outcome and it is not a substitute for regular care.

Why “set, setting, and integration” are central to both approaches

Whether someone talks about PAP or trip therapy, three elements keep recurring:

Set: the inner state, expectations, intentions, and current stress. A turbulent period, sleep deprivation, or high baseline anxiety can color the experience.

Setting: the environment and the people around you. Peace, privacy, physical safety, and reliable guidance are often seen as basic prerequisites for the safest possible experience.

Integration: processing what has arisen and translating it into daily life. This can involve conversations, journaling, bodywork, or taking concrete steps. Integration is often where “insights” gain meaning, but also where confusion can arise if someone is facing it alone.

Nuance is particularly important when dealing with trauma. An intense experience can feel helpful, but it can also be overwhelming. It is therefore wise for providers to focus not only on the session itself, but also on preparation, boundaries, and a plan for what to do if someone becomes disoriented afterward.

Safety and harm reduction: practical questions you can always ask

Because terms such as trip therapy are not protected, concrete safety questions help to assess quality. Consider:

What does the intake look like, and what are the reasons for not providing support to someone? Is attention paid to mental stability, current support, and potential risks?

Who is the facilitator, what is the training, and how are boundaries and consent handled during the session?

What happens in the event of panic, dissociation, or physical symptoms? Is there a clear plan, and is a referral made if necessary?

What does integration look like, and how many contact points are there afterwards?

These types of questions align with harm reduction: not relying on hype or promises, but on realistic preparation and risk mitigation.

Expectations: between hope and caution

The popularity of psychedelic therapies is fueled in part by hopeful stories and research that is still very much in development. This can be inspiring, but it is wise to manage expectations carefully. A single session is not automatically a breakthrough, and “going deep” is not the same as lasting change. Furthermore, it is not always possible to predict in advance what someone will encounter during a session.

It helps to formulate intentions rather than hard goals. For example: more self-insight, gentleness, learning to better manage emotions, or exploring themes that are difficult to reach in talk therapy. That is different from a promise that symptoms will disappear.

Conclusion

Trip therapy and PAP are similar because both link an altered experience of consciousness to guidance, but they often differ in context, language, protocol, and availability. This is particularly relevant with MDMA, as MDMA sessions can currently only be discussed and approached within the context of scientific research or via harm reduction. Those wishing to explore their options would do well to focus less on labels and more on concrete quality and safety characteristics such as screening, set and setting, and integration. If you wish to orient yourself further in a practical way, you can do so via sign up for an MDMA session request more information about the working method and preconditions within a harm reduction framework.

MDMA THERAPY